SoftVue 3D is intended as an assist to digital mammography for screening asymptomatic women with dense tissue and was cleared for use by the U.S. Food and Drug Administration in October 2021. When paired with mammography, SoftVue has been shown to identify up to 20% more cancers while also reducing false positives and decreasing unnecessary recalls and biopsies, the company said.

University of Rochester Medical Center is now the third medical center in the world offering dense breast cancer screening with SoftVue, Delphinus added.